Correction to: The Effectiveness and Safety of Percutaneous Platelet-Rich Plasma and Bone Marrow Aspirate Concentrate for the Treatment of Suspected Discogenic Low Back Pain: a Comprehensive Review

<sec><title>Study Design</title>Preliminary clinical trial.</sec><sec><title>Purpose</title>To determine the safety and initial efficacy of intradiscal injection of autologous platelet-rich plasma (PRP) releasate in patients with discogenic low back pain.</sec><sec><title>Overview of Literature</title>PRP, which is comprised of autologous growth factors and cytokines, has been widely used in the clinical setting for tissue regeneration and repair. PRP has been shown <italic>in vitro</italic> and <italic>in vivo</italic> to potentially stimulate intervertebral disc matrix metabolism.</sec><sec><title>Methods</title>Inclusion criteria for this study included chronic low back pain without leg pain for more than 3 months; one or more lumbar discs (L3/L4 to L5/S1) with evidence of degeneration, as indicated via magnetic resonance imaging (MRI); and at least one symptomatic disc, confirmed using standardized provocative discography. PRP releasate, isolated from clotted PRP, was injected into the center of the nucleus pulposus. Outcome measures included the use of a visual analog scale (VAS) and the Roland-Morris Disability Questionnaire (RDQ), as well as X-ray and MRI (T2-quantification).</sec><sec><title>Results</title>Data were analyzed from 14 patients (8 men and 6 women; mean age, 33.8 years). The average follow-up period was 10 months. Following treatment, no patient experienced adverse events or significant narrowing of disc height. The mean pain scores before treatment (VAS, 7.5±1.3; RDQ, 12.6±4.1) were significantly decreased at one month, and this was generally sustained throughout the observation period (6 months after treatment: VAS, 3.2±2.4, RDQ; 3.6±4.5 and 12 months: VAS, 2.9±2.8; RDQ, 2.8±3.9; <italic>p</italic><0.01, respectively). The mean T2 values did not significantly change after treatment.</sec><sec><title>Conclusions</title>We demonstrated that intradiscal injection of autologous PRP releasate in patients with low back pain was safe, with no adverse events observed during follow-up. Future randomized controlled clinical studies should be performed to systematically evaluate the effects of this therapy.</sec>

Download Full-text

Intradiscal Platelet-Rich Plasma Injection for Discogenic Low Back Pain and Correlation with Platelet Concentration: A Prospective Clinical Trial

Pain Medicine ◽

10.1093/pm/pnaa254 ◽

2020 ◽

Vol 21 (11) ◽

pp. 2719-2725

Author(s):

Dhruv Jain ◽

Titiksha Goyal ◽

Nimisha Verma ◽

Anil Kumar Paswan ◽

Rajeev Kumar Dubey

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Rating Scale ◽

Platelet Rich Plasma ◽

Pain Clinic ◽

Low Back ◽

Discogenic Pain ◽

Platelet Counts ◽

Discogenic Low Back Pain ◽

Platelet Concentration

Abstract Objective Discogenic pain is common cause of low back ache and may result in significant morbidity. Platelet-rich plasma (PRP) is an upcoming regenerative therapy that has treatment potential for this condition. The objective of this study was to correlate platelet concentration in intradiscal PRP injection with improvement in low back pain and functional status at three and six months. Design Prospective single-arm interventional study. Setting Outpatient pain clinic and operation theater. Subjects Twenty-five patients with discogenic pain diagnosed by clinical means and imaging with confirmation by provocative discography were recruited. Methods The patients received PRP injection at a single or multiple disc levels. Preprocedure numerical rating scale (NRS) pain scores and Oswestry Disability Index (ODI) scores were calculated. Platelet counts of patients and PRP samples were measured. At three and six months postprocedure, NRS and ODI scores were measured, and improvement in these scores was correlated with platelet concentrations in the PRP sample. Results Twenty patients completed the study. The improvement in NRS and ODI scores positively correlated with platelet concentrations in the PRP sample. We determined the correlation coefficient (r) of platelet concentrations with a reduction in NRS at three months (r = 0.65) and six months (r = 0.73) and in ODI score at three months (r = 0.72) and six months (r = 0.7). Conclusions This study supports the use of intradiscal PRP for treatment of discogenic pain with preferably higher platelet counts to elicit a favorable response.

Download Full-text

Intradiscal platelet-rich plasma (PRP) injections for discogenic low back pain: an update

International Orthopaedics ◽

10.1007/s00264-016-3178-3 ◽

2016 ◽

Vol 40 (6) ◽

pp. 1321-1328 ◽

Cited By ~ 34

Author(s):

Michael Monfett ◽

Julian Harrison ◽

Kwadwo Boachie-Adjei ◽

Gregory Lutz

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Platelet Rich Plasma ◽

Low Back ◽

Discogenic Low Back Pain

Download Full-text

Platelet-Rich Plasma for the Treatment of Low Back Pain: a Comprehensive Review

Current Pain and Headache Reports ◽

10.1007/s11916-019-0797-6 ◽

2019 ◽

Vol 23 (7) ◽

Cited By ~ 4

Author(s):

Ivan Urits ◽

Omar Viswanath ◽

Annemarie C. Galasso ◽

Emily R. Sottosani ◽

Keenan M. Mahan ◽

...

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Platelet Rich Plasma ◽

Low Back ◽

Comprehensive Review

Download Full-text

Intradiscal Platelet-Rich Plasma Injection for Chronic Discogenic Low Back Pain: Preliminary Results from a Prospective Trial

Pain Medicine ◽

10.1093/pm/pnv053 ◽

2015 ◽

pp. pnv053 ◽

Cited By ~ 13

Author(s):

David Levi ◽

Scott Horn ◽

Sara Tyszko ◽

Josh Levin ◽

Charles Hecht-Leavitt ◽

...

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Platelet Rich Plasma ◽

Prospective Trial ◽

Low Back ◽

Preliminary Results ◽

Plasma Injection ◽

Discogenic Low Back Pain

Download Full-text

Platelet-Rich Plasma Releasate versus Corticosteroid for the Treatment of Discogenic Low Back Pain: A Double-Blind Randomized Controlled Trial

Journal of Clinical Medicine ◽

10.3390/jcm11020304 ◽

2022 ◽

Vol 11 (2) ◽

pp. 304

Author(s):

Koji Akeda ◽

Kohshi Ohishi ◽

Norihiko Takegami ◽

Takao Sudo ◽

Junichi Yamada ◽

...

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Platelet Rich Plasma ◽

Controlled Trial ◽

Controlled Clinical Trial ◽

Walking Ability ◽

Low Back ◽

Disability Score ◽

Double Blind ◽

Discogenic Low Back Pain

Clinical application of platelet-rich plasma is gaining popularity in treating low back pain (LBP). This study investigated the efficacy and safety of platelet-rich plasma releasate (PRPr) injection into degenerated discs of patients with discogenic LBP. A randomized, double-blind, active-controlled clinical trial was conducted. Sixteen patients with discogenic LBP received an intradiscal injection of either autologous PRPr or corticosteroid (CS). Patients in both groups who wished to have PRPr treatment received an optional injection of PRPr eight weeks later. The primary outcome was change in VAS from baseline at eight weeks. Secondary outcomes were pain, disability, quality of life (QOL), image analyses of disc degeneration, and safety for up to 60 weeks. The VAS change at eight weeks did not significantly differ between the two groups. Fifteen patients received the optional injection. Compared to the CS group, the PRPr group had a significantly improved disability score at 26 weeks and walking ability scores at four and eight weeks. Radiographic disc height and MRI grading score were unchanged from baseline. PRPr caused no clinically important adverse events. PRPr injection showed clinically significant improvements in LBP intensity equal to that of CS. PRPr treatment relieved pain, and improved disability and QOL during 60 weeks of observation.

Download Full-text